SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROS... ( S6973 allows up to 50% sucrose reduc...)

SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER

Date:7/29/2008

S6973 allows up to 50% sucrose reduction while maintaining the sweet taste

of natural sugar

SAN DIEGO, CA, July 29, 2008 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that it has initiated development activities for a new sucrose enhancer, S6973. Sucrose (otherwise known as common table sugar) is widely used in many food and beverage products. Taste tests have demonstrated that S6973 enables the reduction of up to 50% of the sucrose present in product prototypes while maintaining the sweet taste of natural sugar.

"Senomyx believes that S6973 has the potential to be used to enhance the sweet taste of sucrose in numerous food and beverage products," said Kent Snyder, President, Chief Executive Officer, and Chairman of the Board of Senomyx. "The discovery of S6973 is a major scientific accomplishment and represents a significant commercial opportunity for Senomyx. Flavor ingredients that enable a meaningful reduction in sucrose without compromising taste would provide consumers with new choices for products with lower calories and therefore improved nutritional profiles."

Unlike typical sugar alternatives, S6973 does not have a sweet taste of its own in taste tests with product prototypes. Instead, it is a unique flavor ingredient intended to amplify the sweet taste of the sugar present in a food or beverage. "Taste tests conducted by Senomyx have shown that S6973 enhanced the sweet taste of yogurt, cereal, and cookie prototypes, as well as powdered and other beverages," noted John Poyhonen, Senior Vice
'/>"/>

SOURCE Senomyx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC
2. Senomyx Announces Conclusion of Discovery and Development Collaboration With Kraft Foods Global, Inc.
3. Cochlear Announces Milestone in Hearing Restoration With 120,000 Nucleus(R) Cochlear Implants
4. Beckman Coulter Announces Second Quarter 2008 Results
5. Rochester Medical Announces Third Quarter 2008 Earnings Conference Call July 31, 2008
6. Instrumentation Laboratory Announces Contract for Multi-Parameter Testing Products with Broadlane
7. Global Probiotics Council Announces First Awardees for New Young Investigator Grant for Probiotics Research
8. Monsanto Announces Key Regulatory Approvals for Roundup Ready 2 Yield(TM) Soybeans; Product Remains on Track for 2009 Launch
9. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
10. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva

Post Your Comments:

(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...

(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...

(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering. ...

(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...

Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2 RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3 Bioinformatics Market Worth $7.5 Billion by 2017 2 Bioinformatics Market Worth $7.5 Billion by 2017 3 Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2 Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3 Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2 Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3

[0] RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants [0] Bioinformatics Market Worth $7.5 Billion by 2017 [0] Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 [0] Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.

... Eastern Time -, SAN FRANCISCO, Nov. 10 ... corporate progress and financial,results for the quarter ended September ... of significant,achievement and progress and was capped with the ... collaboration not only gives us,access to a world-class partner ...

... Conference Call Today To Discuss the Data and Ongoing ... Clinical Development Programs, ... announced today top-line data from its,SB-509-601 clinical trial, one of Sangamo,s ... SB-509 for diabetic,neuropathy (DN). The data demonstrate that repeat administration of ...

... Divestitures of Non-Core Product Lines -, HOPKINTON, ... CALP ) today reported third quarter financial,results ... line divestitures: the,sale of its AutoTrace(R) product line ... of its Pharmaceutical Development and Quality Analysis,(PDQ) product ...

Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs

(Date:6/18/2013)... DNA and this modification can occur in millions ... scientists believed that this epigenetic phenomenon actively reduced ... of researchers from the University of Geneva (UNIGE), ... the Faculty of Medicine, reveals that this is ... may play both a passive and active role ...

(Date:6/17/2013)... in patients with severe brain infections in Vietnam. Further ... responsible for the symptoms of disease. , The virus ... 644 patients with severe brain infections in the study, ... the 122 patients with non-infectious brain disorders that were ... system are often fatal and patients who do survive, ...

(Date:6/17/2013)... improving original foundations with more modern elements. Using this ... Kenneth P. Dietrich School of Arts and Sciences have ... delivery, gas storage, and gas transport more efficient and ... the latest issue of the Journal of the ... recent work builds upon Pitt Associate Professor of Chemistry ...

Breaking Biology News(10 mins):The secret of DNA methylation 2 New virus isolated from patients with severe brain infections 2 New virus isolated from patients with severe brain infections 3 'Chemical architects' build materials with potential applications in drug delivery and gas storage 2

[0] The secret of DNA methylation [0] New virus isolated from patients with severe brain infections [0] 'Chemical architects' build materials with potential applications in drug delivery and gas storage

... relatedness of an animal food protein to a human protein ... by scientists from the Institute of Food Research in Norwich ... proteins have the potential to become allergens, but the study ... to act as allergens depends on their evolutionary distance from ...

... pathway that plays a critical role in the growth ... important insight into the development of the vascular system ... inhibiting the blood vessels that fuel cancers, diabetic eye ... published online on Oct. 14 in Nature Genetics. was ...

... 2007Today at the Prostate Cancer Foundations Annual Scientific Retreat, ... foods such as tomatoes and fish, maintaining a healthy ... help prevent prostate cancer, and help men live healthier ... will be diagnosed with prostate cancer in their lifetime, ...

Cached Biology News:Animal food allergens unmasked 2 Study reveals a key to blood vessel growth and possible drug target 2 Study reveals a key to blood vessel growth and possible drug target 3 Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2 Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3

Animal food allergens unmasked Study reveals a key to blood vessel growth and possible drug target Leading researchers to reveal comprehensive dos and don'ts for prostate cancer

Blue Standard is 3-cyano-7-hydroxycoumarin....

Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...

6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...

Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....

Biology Products:

Fluorescent Standards Blue Standard from Invitrogen Fluorescent Standards Cyan Standard from Invitrogen 6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE) from Molecular Probes (Invitrogen)Rabbit Anti-Human ECE1 Polyclonal Antibody, Unconjugated from Atlas Antibodies